Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Ovarian Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Ovarian Cancer. This report contains market size and forecasts of Gene Therapy for Ovarian Cancer in global, including the following market information:
Global Gene Therapy for Ovarian Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene Therapy for Ovarian Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Gene therapy is expected to be one of the next big paradigm shift in pharmacology due to the extensive on-going research studies, both at academic and industry level. Gene therapy is one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy is gaining attention as it has the potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
We surveyed the Gene Therapy for Ovarian Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for Ovarian Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Ovarian Cancer Market Segment Percentages, by Type, 2022 (%)
Intravenous
Intratumoral
Intraperitoneal
Global Gene Therapy for Ovarian Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Ovarian Cancer Market Segment Percentages, by Application, 2022 (%)
Ovarian Cancer (Unspecified)
Recurrent Ovarian Epithelial Cancer
Platinum-Resistant Ovarian Cancer
Global Gene Therapy for Ovarian Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene Therapy for Ovarian Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for Ovarian Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene Therapy for Ovarian Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takara Bio
VBL Therapeutics
CELSION
Targovax
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Ovarian Cancer, market overview.
Chapter 2: Global Gene Therapy for Ovarian Cancer market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Ovarian Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Ovarian Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Gene Therapy for Ovarian Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Therapy for Ovarian Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Therapy for Ovarian Cancer Overall Market Size
2.1 Global Gene Therapy for Ovarian Cancer Market Size: 2022 VS 2029
2.2 Global Gene Therapy for Ovarian Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene Therapy for Ovarian Cancer Players in Global Market
3.2 Top Global Gene Therapy for Ovarian Cancer Companies Ranked by Revenue
3.3 Global Gene Therapy for Ovarian Cancer Revenue by Companies
3.4 Top 3 and Top 5 Gene Therapy for Ovarian Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gene Therapy for Ovarian Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene Therapy for Ovarian Cancer Players in Global Market
3.6.1 List of Global Tier 1 Gene Therapy for Ovarian Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene Therapy for Ovarian Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Gene Therapy for Ovarian Cancer Market Size Markets, 2022 & 2029
4.1.2 Intravenous
4.1.3 Intratumoral
4.1.4 Intraperitoneal
4.2 By Type - Global Gene Therapy for Ovarian Cancer Revenue & Forecasts
4.2.1 By Type - Global Gene Therapy for Ovarian Cancer Revenue, 2018-2023
4.2.2 By Type - Global Gene Therapy for Ovarian Cancer Revenue, 2024-2029
4.2.3 By Type - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gene Therapy for Ovarian Cancer Market Size, 2022 & 2029
5.1.2 Ovarian Cancer (Unspecified)
5.1.3 Recurrent Ovarian Epithelial Cancer
5.1.4 Platinum-Resistant Ovarian Cancer
5.2 By Application - Global Gene Therapy for Ovarian Cancer Revenue & Forecasts
5.2.1 By Application - Global Gene Therapy for Ovarian Cancer Revenue, 2018-2023
5.2.2 By Application - Global Gene Therapy for Ovarian Cancer Revenue, 2024-2029
5.2.3 By Application - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Gene Therapy for Ovarian Cancer Market Size, 2022 & 2029
6.2 By Region - Global Gene Therapy for Ovarian Cancer Revenue & Forecasts
6.2.1 By Region - Global Gene Therapy for Ovarian Cancer Revenue, 2018-2023
6.2.2 By Region - Global Gene Therapy for Ovarian Cancer Revenue, 2024-2029
6.2.3 By Region - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Gene Therapy for Ovarian Cancer Revenue, 2018-2029
6.3.2 US Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.3.3 Canada Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.3.4 Mexico Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Gene Therapy for Ovarian Cancer Revenue, 2018-2029
6.4.2 Germany Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4.3 France Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4.4 U.K. Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4.5 Italy Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4.6 Russia Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.4.8 Benelux Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Gene Therapy for Ovarian Cancer Revenue, 2018-2029
6.5.2 China Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.5.3 Japan Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.5.4 South Korea Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.5.6 India Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Gene Therapy for Ovarian Cancer Revenue, 2018-2029
6.6.2 Brazil Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.6.3 Argentina Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gene Therapy for Ovarian Cancer Revenue, 2018-2029
6.7.2 Turkey Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.7.3 Israel Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Gene Therapy for Ovarian Cancer Market Size, 2018-2029
6.7.5 UAE Gene Therapy for Ovarian Cancer Market Size, 2018-2029
7 Gene Therapy for Ovarian Cancer Companies Profiles
7.1 Takara Bio
7.1.1 Takara Bio Company Summary
7.1.2 Takara Bio Business Overview
7.1.3 Takara Bio Gene Therapy for Ovarian Cancer Major Product Offerings
7.1.4 Takara Bio Gene Therapy for Ovarian Cancer Revenue in Global Market (2018-2023)
7.1.5 Takara Bio Key News & Latest Developments
7.2 VBL Therapeutics
7.2.1 VBL Therapeutics Company Summary
7.2.2 VBL Therapeutics Business Overview
7.2.3 VBL Therapeutics Gene Therapy for Ovarian Cancer Major Product Offerings
7.2.4 VBL Therapeutics Gene Therapy for Ovarian Cancer Revenue in Global Market (2018-2023)
7.2.5 VBL Therapeutics Key News & Latest Developments
7.3 CELSION
7.3.1 CELSION Company Summary
7.3.2 CELSION Business Overview
7.3.3 CELSION Gene Therapy for Ovarian Cancer Major Product Offerings
7.3.4 CELSION Gene Therapy for Ovarian Cancer Revenue in Global Market (2018-2023)
7.3.5 CELSION Key News & Latest Developments
7.4 Targovax
7.4.1 Targovax Company Summary
7.4.2 Targovax Business Overview
7.4.3 Targovax Gene Therapy for Ovarian Cancer Major Product Offerings
7.4.4 Targovax Gene Therapy for Ovarian Cancer Revenue in Global Market (2018-2023)
7.4.5 Targovax Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Gene Therapy for Ovarian Cancer Market Opportunities & Trends in Global Market
Table 2. Gene Therapy for Ovarian Cancer Market Drivers in Global Market
Table 3. Gene Therapy for Ovarian Cancer Market Restraints in Global Market
Table 4. Key Players of Gene Therapy for Ovarian Cancer in Global Market
Table 5. Top Gene Therapy for Ovarian Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Gene Therapy for Ovarian Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Gene Therapy for Ovarian Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Gene Therapy for Ovarian Cancer Product Type
Table 9. List of Global Tier 1 Gene Therapy for Ovarian Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene Therapy for Ovarian Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Gene Therapy for Ovarian Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Gene Therapy for Ovarian Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Gene Therapy for Ovarian Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Gene Therapy for Ovarian Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Gene Therapy for Ovarian Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Gene Therapy for Ovarian Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Takara Bio Company Summary
Table 31. Takara Bio Gene Therapy for Ovarian Cancer Product Offerings
Table 32. Takara Bio Gene Therapy for Ovarian Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Takara Bio Key News & Latest Developments
Table 34. VBL Therapeutics Company Summary
Table 35. VBL Therapeutics Gene Therapy for Ovarian Cancer Product Offerings
Table 36. VBL Therapeutics Gene Therapy for Ovarian Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. VBL Therapeutics Key News & Latest Developments
Table 38. CELSION Company Summary
Table 39. CELSION Gene Therapy for Ovarian Cancer Product Offerings
Table 40. CELSION Gene Therapy for Ovarian Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. CELSION Key News & Latest Developments
Table 42. Targovax Company Summary
Table 43. Targovax Gene Therapy for Ovarian Cancer Product Offerings
Table 44. Targovax Gene Therapy for Ovarian Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Targovax Key News & Latest Developments
List of Figures
Figure 1. Gene Therapy for Ovarian Cancer Segment by Type in 2022
Figure 2. Gene Therapy for Ovarian Cancer Segment by Application in 2022
Figure 3. Global Gene Therapy for Ovarian Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Gene Therapy for Ovarian Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Gene Therapy for Ovarian Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene Therapy for Ovarian Cancer Revenue in 2022
Figure 8. By Type - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 16. US Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 28. China Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Gene Therapy for Ovarian Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Gene Therapy for Ovarian Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Takara Bio Gene Therapy for Ovarian Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. VBL Therapeutics Gene Therapy for Ovarian Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. CELSION Gene Therapy for Ovarian Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Targovax Gene Therapy for Ovarian Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
